Giacomina Massaro-Giordano, MD
Cornea and External Diseases Specialist · Philadelphia, PANPI 1891806543
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,655 of the $64,113 with a category attached, or 63.4%. 12 manufacturers reported payments, led by Dompe US, Inc. at 57.9% of the total.
Across 58 payments — averaging $1105.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$37K
- Dompe Farmaceutici S.p.a.$13K
- Oyster Point Pharma, Inc.$3K
- Alcon$3K
- Kala Pharmaceuticals, Inc.$3K
- Tarsus Pharmaceuticals, Inc.$2K
- plus $3K from 6 others
Across 64 payments — averaging $13,326 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe Farmaceutici S.p.a.$422K
- Oyster Point Pharma, Inc.$248K
- Dompe US, Inc.$166K
- Novartis$17K
- AbbVie$102
What the payments were for
- Consulting fees$40,65563%
- Speaking & faculty fees$5,6819%
- Travel & lodging$15,12724%
- Food & beverage$2,6504%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 25 | $37,122 |
| Dompe Farmaceutici S.p.a. | 9 | $12,520 |
| Oyster Point Pharma, Inc. | 5 | $3,382 |
| Alcon | 4 | $3,103 |
| Kala Pharmaceuticals, Inc. | 2 | $2,730 |
| Tarsus Pharmaceuticals, Inc. | 4 | $2,420 |
| Alcon Research LLC | 1 | $1,500 |
| AbbVie(2 entities) | 4 | $912 |
| Harrow Eye, LLC | 1 | $212 |
| Bausch & Lomb Americas Inc. | 1 | $122 |
| Ocular Therapeutix, Inc. | 1 | $60 |
| Sight Sciences, Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few cornea and external diseases specialist providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 31 | $1,208,845 |
| MieboPerfluorohexyloctane/Pf | 253 | $246,854 |
| RestasisCyclosporine | 181 | $218,041 |
| XdemvyLotilaner | 90 | $165,087 |
| XiidraLifitegrast | 88 | $126,562 |
| TyrvayaVarenicline Tartrate | 87 | $110,925 |
| VevyeCyclosporine | 96 | $70,383 |
| Cyclosporine | 120 | $62,273 |
| CequaCyclosporine | 38 | $42,474 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 821 | $30,483 |
| ErythromycinErythromycin Base | 1,287 | $13,667 |
| Restasis MultidoseCyclosporine | 12 | $13,550 |
| CiloxanCiprofloxacin Hcl | 40 | $11,230 |
| TobradexTobramycin/Dexamethasone | 16 | $4,147 |
| Loteprednol Etabonate | 20 | $2,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $37,122 | $1,208,84531 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $122 | $373,416341 claims |
| AbbVieRestasis, Restasis Multidose | $912 | $231,591193 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $2,420 | $165,08790 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $3,382 | $110,92587 claims |
| Harrow Eye, LLCVevye | $212 | $70,38396 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Philadelphia
- Stephen OrlinPhiladelphia$3K
- Michael SulewskiPhiladelphia$829
- Ashley KhaliliPhiladelphia$96
- Vatinee BunyaPhiladelphia$0
- Brian ShaferPlymouth Meeting$736K
- Stuart CarterAllentown$4K
- Hamza PashaCranberry Township$3K
- Kevin ShahWyomissing$3K
- Mira AminNorth Wales$2K
- Sabrina MukhtarPittsburgh$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.